Trial NCT04411628
Publication J2W-MC-PYAA - Chen P, Clin Pharmacol Ther (2021) (published paper)
Primary outcome on the report: Safety and tolerability, including adverse events (AEs), serious adverse events (SAEs), and discontinuations due to AEs

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.